Compare iShares China Large-Cap ETF (FXI) vs Nuvalent Inc (NUVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares China Large-Cap ETF vs Nuvalent Inc — how do they compare? iShares China Large-Cap ETF trades at $34.54, while Nuvalent Inc trades at $123.96 (market cap $9.81B). The key difference: Nuvalent Inc is trading nearer its 52-week high, iShares China Large-Cap ETF nearer its low. Which is the better fit depends on your goals.
| FXI | NUVL | |
|---|---|---|
52-Week High | $41.75 | $123.96 |
52-Week Low | $31.59 | $72.16 |
Market Cap | — | $9.81B |
Sector | — | Technology |
Enterprise Value | — | $8.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The iShares China Large-Cap ETF (FXI) trades at $34.535, up 2.27% on the day, with technical indicators showing a bullish overall signal despite some overbought RSI readings. Recent news highlights China's significant push into AI and electric vehicles, including a reported $295 billion AI infrastructure plan and a 30% NEV fleet target by 2030, which could benefit the large-cap Chinese companies held within the fund.
The outlook for FXI is tied to China's economic policy execution and its success in strategic sectors like AI and EVs. Key opportunities include exposure to state-backed industrial and tech giants, while risks stem from U.S.-China tech rivalry, regulatory shifts, and the potential for Chinese equities to act as a value trap despite apparent undervaluation.
Nuvalent (NUVL) trades at $123.96, unchanged on the day, amid a pending $124 per share acquisition by GSK. The stock shows a bullish technical signal with moving averages supporting upside, though RSI levels suggest overbought conditions. Fundamentally, the company remains unprofitable with negative ROE and ROA, while cash flow is sustained by financing activities. Recent news is dominated by merger investigations and strategic rationale for the GSK deal.
The investment outlook hinges on the acquisition closing at $124, offering limited upside from current levels. Risks include shareholder litigation and regulatory scrutiny, but the deal provides a clear exit amid ongoing losses. Analyst sentiment is mixed with a slight hold bias, reflecting uncertainty around deal completion and fairness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →About Nuvalent Inc
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →
